Canada-based non-invasive diagnostic tests provider Nanostics has teamed up with OncoHelix to provide its ClarityDX Prostate to healthcare providers and men in the Middle East.
OncoHelix is a provider of advanced molecular and immune diagnostics that has developed a portfolio of precision oncology tests alongside wellness and reproductive health tests.
Nanostics’ ClarityDX Prostate uses biological data, clinical information, and AI models to create a risk score for aggressive prostate cancer screening.
It helps men and their healthcare providers make more informed decisions after a high prostate-specific antigen (PSA) test result or abnormal digital rectal examination (DRE) result.
OncoHelix CEO Faisal Khan said: “We are thrilled to partner with Nanostics to bring the ClarityDX Prostate test to the Middle East.
“This advanced diagnostic tool will empower healthcare providers with better, data-driven insights, enabling earlier detection and more targeted treatment for men at risk of aggressive prostate cancer in the region.”
OncoHelix offers advanced molecular diagnostics and immune profile testing to the Middle East and North Africa (MENA) region through OncoHelix-coLAB in Burjeel Medical City, Abu Dhabi.
OncoHelix-coLAB is a joint venture between OncoHelix and Burjeel Holdings, a large-scale healthcare provider in the Middle East.
The facility will now provide Nanostics’ ClarityDX Prostate diagnostic solution to men, who are at risk of having aggressive prostate cancer.
The addition of its ClarityDX Prostate test will further enhance patient diagnostics and treatment outcomes in the MENA region, said Nanostics.
Nanostics CEO and the University of Alberta Bird Dogs chair of translational oncology John Lewis said: “Partnering with OncoHelix, another Alberta-based company, to bring ClarityDX Prostate to men in the Middle East really shows how relevant Alberta-developed technology has become to the world.
“ClarityDX Prostate is a powerful diagnostic tool that can help identify men with aggressive prostate cancer early. We want all men to benefit from early detection leading to better outcomes.”
Earlier this year, OncoHelix partnered with cloud-native healthcare technology company SOPHiA GENETICS to implement MSK-ACCESS powered with SOPHiA DDM.
